Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Heat shock protein 90 kDa (Hsp90) is a crucial molecular chaperone implicated in cancer progression.
• Mitochondrial function reprogramming is a hallmark of cancer, presenting a therapeutic target.
• Hsp90 inhibitors are being developed as potential anti-cancer agents.

Purpose of the Study:

• To develop novel triphenylphosphonium (TPP)-conjugated Hsp90 C-terminal inhibitors.
• To evaluate the anti-proliferative activity of these novel compounds.
• To assess the mitochondrial accumulation of TPP-conjugated inhibitors.

Main Methods:

• Synthesis of TPP-conjugated Hsp90 C-terminal inhibitors.
• In vitro anti-proliferative assays using various cancer cell lines.
• Mitochondrial localization studies.

Main Results:

• TPP-conjugated Hsp90 C-terminal inhibitors demonstrated increased anti-proliferative activity compared to parent compounds.
• The developed compounds effectively accumulated in cancer cell mitochondria.
• Enhanced efficacy was observed across multiple cancer cell lines.

Conclusions:

• TPP conjugation enhances the anti-cancer efficacy of Hsp90 C-terminal inhibitors.
• Mitochondrial targeting via TPP conjugation represents a promising strategy for cancer therapy.
• These novel compounds warrant further investigation as potential anti-cancer drugs.